Hematologic Oncology: IMO-4200
IMO-4200, a dual agonist of TLR7 and TLR8, is a lead drug candidate for the treatment of hematologic oncology.
Treatment with IMO-4200 in combination with approved cancer therapy agents such as the anti-CD20 antibody rituximab or the proteosome inhibitor bortezomib has shown improved antitumor activity and increased survival in preclinical models of lymphoma. (Press Release).
- Antitumor Activity of an RNA-Based Agonist of TLR7 and 8 in Preclinical Models of Hematological Malignancies at the 52nd Annual Meeting of the American Society of Hematology, December 2010
- IMO-4200, a Novel TLR7 and TLR8 Dual Agonist, Enhances Antitumor Effect of Ofatumumab, Rituximab and Cytotoxics in Preclinical Models of Hematological Malignancies at the 53nd Annual Meeting of the American Society of Hematology, December 2011